The evolution of precision medicine in cancer diagnostics
The evolution of precision medicine in cancer diagnostics began with Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) followed by Immunoassay, Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) based diagnostics. Mass spectrometry will emerge as the next step in the evolution of precision medicine.
State-of-the-art purification kits
therawis diagnostics develops state-of-the-art purification kits for exosomes and immune cells for mass spectrometry applications. The enriched sample preparations of immune cells and exosomes will be subjected to mass spectrometry analysis. The proteomics data acquisition is conducted with state-of-the-art mass spectrometer platform (Bruker).
Data analysis pipelines (based on LASSO and BAYESIAN modelling) will be leveraged towards identification of enriched novel candidate biomarkers that are differentially present in samples from healthy or diseased patients. In parallel graph-based machine learning algorithms will be applied to expand the set of potential biomarkers and annotate the pathways linked to disease patterns. Predictive power of these biomolecules will be tested on a separate dataset by machine learning algorithms and by alternative approaches.
